A new study found that US Preventive Services Task Force guidelines identify nearly 89% of pregnancies at increased risk, but leave 70.3% in the moderate risk category with nonspecific recommendations for aspirin use. The study suggests that these guidelines may influence clinicians' decisions regarding daily aspirin recommendations.
Researchers used data from 9,000 pregnancies to discover and validate RNA signatures that distinguish between severe and mild hypertensive disorders of pregnancy. The study validates Mirvie's simple blood test to predict preeclampsia early, at 17.5-22 weeks gestational age.
Researchers developed a breakthrough technology using Mirvie's RNA platform to identify unique molecular signals in unborn babies. This innovation enables prediction of severe fetal growth restriction, a leading cause of stillbirth.
A new study finds that objective information about preeclampsia risk could drive patient behavior change and motivate pregnant women to follow prevention strategies. The research highlights the potential of personalized risk data to improve pregnancy outcomes and reduce complications.
A comprehensive care plan has been published to prevent preeclampsia, a leading cause of pregnancy-related death in the US. The plan provides specific recommendations for both expecting parents and clinicians, including daily low-dose aspirin, surveillance, and behavioral strategies.